Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel With or Without Bevacizumab for Previously Treated Soft Tissue Sarcoma
NCT07547592Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of bevacizumab in soft tissue sarcoma (STS), sponsored by Yonsei University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07547592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547592.